ESC 365 - Future direction for research in drug therapy.

ESC Premium Access

Future direction for research in drug therapy.

Session: Drug therapy in heart failure

Topic: Pharmacologic therapy

Speaker: Professor J. Teerlink (San Francisco, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

35 presentations

0 follower

4 more presentations in this session

State of the art in drug therapy in chronic heart failure.

Speaker: Professor D. van Veldhuisen (Groningen, NL)

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Speaker: Doctor G. Savarese (Stockholm, SE)

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Speaker: Professor W. Kosmala (Wroclaw, PL)

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Speaker: Doctor P. Paren (Gothenburg, SE)

Access the full session

Drug therapy in heart failure

Speakers: Professor J. Teerlink, Professor D. van Veldhuisen, Doctor G. Savarese, Professor W. Kosmala, Doctor P. Paren

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources